N-methyl-D-aspartate receptor blockade is neuroprotective in experimental autoimmune optic neuritis

Journal of Neuropathology and Experimental Neurology

Volumn 73, Issue 6, 2014, Pages 507-518

  Sühs, Kurt Wolfram ^a   Fairless, Richard ^b   Williams, Sarah K ^b   Heine, Katrin ^c   Cavalié, Adolfo ^c   Diem, Ricarda ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

Glutamate; Memantine; Multiple sclerosis; Neurodegeneration; Neuroprotection; NMDA receptor; Optic neuritis; Retinal ganglion cells

Indexed keywords

CALCIUM; DIZOCILPINE; GLUTAMIC ACID; MEMANTINE; MYELIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLACEBO; 2-HYDROXY-4,4'-DIAMIDINOSTILBENE, METHANESULFONATE SALT; CYTOKINE; DIZOCILPINE MALEATE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NEUROPROTECTIVE AGENT; STILBAMIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL DENSITY; CELL SURVIVAL; CONTROLLED STUDY; EXPERIMENTAL AUTOIMMUNE NEURITIS; FEMALE; HISTOPATHOLOGY; MULTIPLE SCLEROSIS; NERVE CELL; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; OPTIC NERVE; OPTIC NEURITIS; PRIORITY JOURNAL; RAT; RETINA GANGLION CELL; STIMULATION; ANIMAL; BLOOD; CHEMICALLY INDUCED; COMPLICATION; DIAGNOSTIC USE; DRUG EFFECTS; METABOLISM; MYELIN SHEATH; NEWBORN; PATHOLOGY; TOXICITY;

ANIMALS; ANIMALS, NEWBORN; CALCIUM; CELLS, CULTURED; CYTOKINES; DIZOCILPINE MALEATE; FEMALE; MEMANTINE; MYELIN SHEATH; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; NEURITIS, AUTOIMMUNE, EXPERIMENTAL; NEUROPROTECTIVE AGENTS; OLIGODENDROGLIA; OPTIC NERVE; OPTIC NEURITIS; RATS; RETINAL GANGLION CELLS; STILBAMIDINES;

EID: 84901367439     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0000000000000073     Document Type: Article

References (46)

1. Beck RW, Gal RL, Bhatti MT, et al., Optic Neuritis Study Group. Visual function more than 10 years after optic neuritis: Experience of the optic neuritis treatment trial. Am J Opthalmol 2004;137:77-83
2. Hickman SJ, Brierley CM, Brex PA, et al. Continuing optic nerve atrophy following optic neuritis: A serial MRI study. Mult Scler 2002;8:339-42
3. Trip SA, Schlottmann PG, Jones SJ, et al. Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol 2005;58:383-91
4. Trip SA, Schlottmann PG, Jones SJ, et al. Optic nerve atrophy and retinal nerve fibre layer thinning following optic neuritis: Evidence that axonal loss is a substrate of MRI-detected atrophy. Neuroimage 2006;31:286-89
5. Meyer R, Weissert R, Diem R, et al. Acute neuronal apoptosis in a rat model of multiple sclerosis. J Neurosci 2001;21:6214-20
6. Hobom M, Storch MK, Weissert R, et al. Mechanisms and time course of neuronal degeneration in experimental autoimmune encephalomyelitis. Brain Pathol 2004;14:148-57
7. Sättler MB, Togni M, Gadjanski I, et al. Strain-specific susceptibility for neurodegeneration in a rat model of autoimmune optic neuritis. J Neuroimmunol 2008;193:77-86
8. Fairless R, Williams SK, Hoffmann B, et al. Preclinical retinal neurodegeneration in a model of multiple sclerosis. J Neurosci 2012;32: 5585-97
9. Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond. Nat Rev Drug Discov 2006;5:160-70
10. Sarchielli P, Greco L, Floridi A, et al. Excitatory amino acids and multiple sclerosis: Evidence from cerebrospinal fluid. Arch Neurol 2003;60: 1082-88
11. Stover JF, Pleines UE, Morganti-Kossmann MC, et al. Neurotransmitters in cerebrospinal fluid reflect pathological activity. Eur J Clin Invest 1997; 27:1038-43
12. Srinivasan R, Sailasuta N, Hurd R, et al. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 2005;128:1016-25
13. Maier K, Merkler D, Gerber J, et al. Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation. Neurobiol Dis 2007;25:514-25
14. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 2000;6:67-70
15. Smith T, Groom A, Zhu B, et al. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med 2000;6:62-66
16. Paul C, Bolton C. Modulation of blood brain barrier dysfunction and neurological deficits during acute experimental allergic encephalomyelitis by the N-methyl-D-aspartate receptor antagonist memantine. J Pharmacol Exp Ther 2002;302:50-57
17. Wallström E, Diener P, Ljungdahl A, et al. Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis. J Neurol Sci 1996;137:89-96
18. Chen S, Diamond JS. Synaptically released glutamate activates extrasynaptic NMDA receptors on cells in the ganglion cell layer of rat retina. J Neurosci 2002;22:2165-73
19. Fletcher EL, Hack I, Brandstätter JH, et al. Synaptic localization of NMDA receptor subunits in the rat retina. J Comp Neurol 2000;420: 98-112
20. Weissert R, Wallström E, Storch MK, et al. MHC haplotypeYdependent regulation of MOG-induced EAE in rats. J Clin Invest 1998;102:1265-73
21. Chen HS, Wang YF, Rayudu PV, et al. Neuroprotective concentrations of the N-methyl-D-aspartate open channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long term potentiation. Neuroscience 1998;86:1121-32
22. Bolton C, Paul C. MK-801 limits neurovascular dysfunction during experimental allergic encephalomyelitis. J Pharmacol Exp Ther 1997;281: 397-402
23. Bitsch A, Schuchardt J, Bunkowski S, et al. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000;123:1174-83
24. Barres BA, Silverstein BE, Corey DP, et al. Immunological, morphological, and electrophysiological variation among retinal ganglion cells purified by panning. Neuron 1998;1:791-803
25. Qian A, Buller AL, Johnson JW. NR2 subunit-dependence of NMDA receptor channel block by external Mg2+. J Physiol 2005;562:319-31
26. Basso AS, Frenkel D, Quintana FJ, et al. Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J Clin Invest 2008;118:1532-43
27. Diem R, Hobom M, Maier K, et al. Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway. J Neurosci 2003;23:6993-7000
28. Waxman SG. Mechanisms of disease: Sodium channels and neuroprotection in multiple sclerosisVcurrent status. Nat Clin Pract Neurol 2008;4:159-69
29. Gadjanski I, Boretius S, Williams SK, et al. The role of N-type voltage-gated calcium channels in autoimmune optic neuritis. Ann Neurol 2009;66:81-93
30. Chen HS, Pellegrini JW, Aggarwal SK, et al. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: Therapeutic advantage against NMDA receptorYmediated neurotoxicity. J Neurosci 1992;12:4427-36
31. Chen HS, Lipton SA. Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: Uncompetitive antagonism. J Physiol 1992;499:27-46
32. Frankiewicz T, Potier B, Bashir ZI, et al. Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices. Br Pharmacol Soc 1996;117:689-97
33. Andine P, Widermark N, Axelsson R, et al. Characterisation of MK-801Yinduced behaviour as a putative rat model of psychosis. J Pharmacol Exp Ther 1999;290:1393-408
34. Parsons CG, Danysz W, Quack G, et al. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: A review of preclinical data. Neuropharmacology 1999;38:735-67
35. Volbracht C, van Beek J, Zhu C, et al. Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity. Eur J Neurosci 2006;23:2611-22
36. Osborne NN. Memantine reduces alterations to the mammalian retina, in situ, induced by ischemia. Vis Neurosci 1999;16:45-52
37. Reisberg B, Doody R, Stöffler A, et al., Memantine Study Group. Memantine in moderate-to-severe Alzheimer?s disease. N Engl J Med 2003;348:1333-41
38. Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson?s disease dementia or dementia with Lewy bodies: A double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009;8:613-18
39. Tariot PN, Farlow MR, Grossberg GT, et al., Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. J Am Med Assoc 2004;291:317-24
40. Scott GS, Bowman SR, Smith T, et al. Glutamate-stimulated peroxynitrite production in a brain-derived endothelial cell line is dependent on N-methyl-D-aspartate (NMDA) receptor activation. Biochem Pharmacol 2007;73:228-36
41. Shijie J, Takeuchi H, Yawata I, et al. Blockade of glutamate release from microglia attenuates experimental autoimmune encephalomyelitis in mice. Tohoku J Exp Med 2009;217:87-92
42. Hawkins RA. Blood-brain barrier and glutamate. Am J Clin Nutr 2009; 90:867S-74S
43. McDonald JW, Althomsons SP, Hyrc KL, et al. Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptorYmediated excitotoxicity. Nat Med 1998;4(3):291-97
44. Salter MG, Fern R. NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury. Nature 2005;438:1167-71
45. Karadottir R, Cavelier P, Bergersen LH, et al. NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. Nature 2005; 438:1162-66
46. Guo F, Maeda Y, Ko EM, et al. Disruption of NMDA receptors in oligodendroglial lineage cells does not alter their susceptibility to experimental autoimmune encephalomyelitis or their normal development. J Neurosci 2011;32:639-45